{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:01:56Z","timestamp":1792677716319,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Worldwide, hypertensive disorders of pregnancy (HDP) are a leading cause of maternal and neonatal morbidity and mortality (Semin Perinatol 2009;33:130\u20137). This is especially true in the United States where preeclampsia is a leading cause of premature births (Hypertens Pregnancy 2016;35:510\u20139 and Lancet 2008;371:164\u201375). Moreover, this disorder is costly due to the financial burden of the health services needed to care for mothers with preeclampsia and their very often preterm infants (Am J Obstet Gynecol 2017;217:235\u20136). Recently, placental biomarkers have been shown to aid in assessment of the risk of severe preeclampsia. In 2023, the FDA approved the use of soluble feline McDonough sarcoma (fms)-like tyrosine kinase-1 to placental growth factor ratio (sFlt-1\/PlGF) as an additional tool for preeclampsia risk assessment between 23 and 35 weeks\u2019 gestation in high-risk patients in the United States. Use of these biomarkers will improve maternal and fetal\/neonatal outcomes and may assist in decreasing the healthcare burden of these patients by adding to risk assessment and the current diagnosis and management of pregnancies with HDP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>The pathophysiology of preeclampsia stems from abnormal placentation that results in an imbalance of pro- and antiangiogenic factors leading to endothelial and vascular dysfunction and the clinical syndrome of preeclampsia (J Clin Invest 2003;111:649\u201358). The role of the sFlt-1\/PlGF in the prediction of progression to preeclampsia has been demonstrated in multiple studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The goal of this review is to demonstrate the role of placental biomarkers (sFlt-1 and PlGF) in the pathophysiology of preeclampsia, with an emphasis on clinical applications and cost-effectiveness in the United States, using real-world applications as examples.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaf024","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T06:11:55Z","timestamp":1743228715000},"page":"548-558","source":"Crossref","is-referenced-by-count":8,"title":["Placental Biomarker Testing for Evaluation of Suspected Preeclampsia"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-5273","authenticated-orcid":false,"given":"Michelle","family":"Silasi","sequence":"first","affiliation":[{"name":"Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, Mercy Hospital St. Louis , St. Louis, MO ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marly","family":"Azzi","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, University of Chicago Medical Center , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Potchileev","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, University of Chicago Medical Center , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Burns","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, University of Chicago Medical Center , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarosh","family":"Rana","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, University of Chicago Medical Center , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2025050208370668200_hvaf024-B1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.semperi.2009.02.010","article-title":"The global impact of pre-eclampsia and eclampsia","volume":"33","author":"Duley","year":"2009","journal-title":"Semin Perinatol"},{"key":"2025050208370668200_hvaf024-B2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/10641955.2015.1090581","article-title":"Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia\/eclampsia","volume":"34","author":"Shahul","year":"2015","journal-title":"Hypertens Pregnancy"},{"key":"2025050208370668200_hvaf024-B3","first-page":"e59352","article-title":"An observational study of maternal and perinatal outcome in preeclampsia cases in a tertiary care center","volume":"16","author":"Kalambe","year":"2024","journal-title":"Cureus"},{"key":"2025050208370668200_hvaf024-B4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/adc.88.12.1034","article-title":"The confidential enquiry into maternal and child health (cemach)","volume":"88","author":"Weindling","year":"2003","journal-title":"Arch Dis Child"},{"key":"2025050208370668200_hvaf024-B5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.earlhumdev.2016.09.007","article-title":"Preeclampsia; short and long-term consequences for mother and neonate","volume":"102","author":"Bokslag","year":"2016","journal-title":"Early Hum Dev"},{"key":"2025050208370668200_hvaf024-B6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: pathophysiology, challenges, and perspectives","volume":"124","author":"Rana","year":"2019","journal-title":"Circ Res"},{"key":"2025050208370668200_hvaf024-B7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.11604\/pamj.2022.41.82.31413","article-title":"Systematic literature review on the neonatal outcome of preeclampsia","volume":"41","author":"Atamamen","year":"2022","journal-title":"Pan Afr Med J"},{"key":"2025050208370668200_hvaf024-B8","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.25122\/jml-2022-0264","article-title":"Preeclampsia and neonatal outcomes in adolescent and adult patients","volume":"15","author":"Uzunov","year":"2022","journal-title":"J Med Life"},{"key":"2025050208370668200_hvaf024-B9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.hipert.2023.11.006","article-title":"Hypertensive states of pregnancy","volume":"41","author":"Rubio Gonzalez","year":"2024","journal-title":"Hipertens Riesgo Vasc"},{"key":"2025050208370668200_hvaf024-B10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/AOG.0000000000000746","article-title":"Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities","volume":"125","author":"Main","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B11","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: Acog practice bulletin, number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/clinchem\/hvab281","article-title":"Angiogenic biomarkers for risk stratification in women with preeclampsia","volume":"68","author":"Docheva","year":"2022","journal-title":"Clin Chem"},{"key":"2025050208370668200_hvaf024-B13","doi-asserted-by":"crossref","first-page":"103780","DOI":"10.1016\/j.ebiom.2021.103780","article-title":"Clinical tools and biomarkers to predict preeclampsia","volume":"75","author":"MacDonald","year":"2022","journal-title":"EBioMedicine"},{"key":"2025050208370668200_hvaf024-B14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2021.12.003","article-title":"Clinical interpretation and implementation of the sflt-1\/plgf ratio in the prediction, diagnosis and management of preeclampsia","volume":"27","author":"Verlohren","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ando.2016.04.007","article-title":"Angiogenic balance (sflt-1\/plgf) and preeclampsia","volume":"77","author":"Lecarpentier","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"key":"2025050208370668200_hvaf024-B16","doi-asserted-by":"crossref","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid"},{"key":"2025050208370668200_hvaf024-B17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1055\/s-0035-1557924","article-title":"Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of dggg (s1-level, awmf registry no. 015\/018, December 2013)","volume":"75","author":"Stepan","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"Suppl 1","key":"2025050208370668200_hvaf024-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The international federation of gynecology and obstetrics (figo) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"2025050208370668200_hvaf024-B19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"2025050208370668200_hvaf024-B20","first-page":"69","article-title":"Placental-specific sflt-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis","volume":"23","author":"Palmer","year":"2017","journal-title":"Mol Hum Reprod"},{"key":"2025050208370668200_hvaf024-B21","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025050208370668200_hvaf024-B22","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1095\/biolreprod59.6.1540","article-title":"A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation","volume":"59","author":"Clark","year":"1998","journal-title":"Biol Reprod"},{"key":"2025050208370668200_hvaf024-B23","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (vegf) by anti-vegf antibodies and soluble vegf receptor 1 (sflt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem"},{"key":"2025050208370668200_hvaf024-B24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199707103370201","article-title":"Trial of calcium to prevent preeclampsia","volume":"337","author":"Levine","year":"1997","journal-title":"N Engl J Med"},{"key":"2025050208370668200_hvaf024-B25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"issue":"Pt 2","key":"2025050208370668200_hvaf024-B26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ajog.2005.06.033","article-title":"An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sflt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia","volume":"193","author":"Park","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B27","first-page":"261","article-title":"Prediction of adverse outcomes by common definitions of hypertension in pregnancy","volume":"97","author":"Zhang","year":"2001","journal-title":"Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B28","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1373\/clinchem.2004.036715","article-title":"Maternal serum sflt1 concentration is an early and reliable predictive marker of preeclampsia","volume":"50","author":"Hertig","year":"2004","journal-title":"Clin Chem"},{"key":"2025050208370668200_hvaf024-B29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1373\/clinchem.2011.169094","article-title":"The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia","volume":"58","author":"Hagmann","year":"2012","journal-title":"Clin Chem"},{"key":"2025050208370668200_hvaf024-B30","doi-asserted-by":"crossref","first-page":"58.e1","DOI":"10.1016\/j.ajog.2011.07.037","article-title":"The sflt-1\/plgf ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients","volume":"206","author":"Verlohren","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.preghy.2024.01.130","article-title":"Longitudinal changes of angiogenic factors as a potential predictive tool in women with suspected preeclampsia","volume":"35","author":"Montenegro-Mart\u00ednez","year":"2024","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B32","doi-asserted-by":"crossref","first-page":"161.e1","DOI":"10.1016\/j.ajog.2009.09.016","article-title":"An automated method for the determination of the sflt-1\/pigf ratio in the assessment of preeclampsia","volume":"202","author":"Verlohren","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"2S","key":"2025050208370668200_hvaf024-B33","doi-asserted-by":"crossref","first-page":"S1048","DOI":"10.1016\/j.ajog.2020.09.046","article-title":"The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia","volume":"226","author":"Verlohren","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/14767050903184207","article-title":"The use of angiogenic biomarkers to differentiate non-hellp related thrombocytopenia from hellp syndrome","volume":"23","author":"Young","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025050208370668200_hvaf024-B35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.preghy.2020.04.014","article-title":"The sflt-1\/plgf ratio as a triage tool to identify superimposed preeclampsia in women with chronic hypertension in emergency rooms","volume":"21","author":"Hern\u00e1ndez-Pacheco","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B36","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.111.181735","article-title":"Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy","volume":"59","author":"Perni","year":"2012","journal-title":"Hypertension"},{"key":"2025050208370668200_hvaf024-B37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000339935","article-title":"Superimposed preeclampsia in women with chronic kidney disease","volume":"74","author":"Masuyama","year":"2012","journal-title":"Gynecol Obstet Invest"},{"key":"2025050208370668200_hvaf024-B38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ki.2012.348","article-title":"Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers","volume":"83","author":"Rolfo","year":"2013","journal-title":"Kidney Int"},{"key":"2025050208370668200_hvaf024-B39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/HYPERTENSIONAHA.112.201459","article-title":"Differential diagnosis of preeclampsia: remember the soluble fms-like tyrosine kinase 1\/placental growth factor ratio","volume":"60","author":"Verdonk","year":"2012","journal-title":"Hypertension"},{"key":"2025050208370668200_hvaf024-B40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sflt-1:Plgf ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"2025050208370668200_hvaf024-B41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","article-title":"Short-term prediction of adverse outcomes using the sflt-1 (soluble fms-like tyrosine kinase 1)\/plgf (placental growth factor) ratio in Asian women with suspected preeclampsia","volume":"74","author":"Bian","year":"2019","journal-title":"Hypertension"},{"key":"2025050208370668200_hvaf024-B42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/s41440-021-00629-x","article-title":"Short-term prediction of preeclampsia using the sflt-1\/plgf ratio: a subanalysis of pregnant Japanese women from the prognosis Asia study","volume":"44","author":"Ohkuchi","year":"2021","journal-title":"Hypertens Res"},{"key":"2025050208370668200_hvaf024-B43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: inspire","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension"},{"key":"2025050208370668200_hvaf024-B44","doi-asserted-by":"crossref","first-page":"e11226","DOI":"10.1016\/j.heliyon.2022.e11226","article-title":"Blood biomarkers to predict the onset of pre-eclampsia: a systematic review and meta-analysis","volume":"8","author":"Danielli","year":"2022","journal-title":"Heliyon"},{"key":"2025050208370668200_hvaf024-B45","first-page":"14","article-title":"Serum biomarkers for the prediction and diagnosis of preeclampsia: a meta-analysis","volume":"17","author":"Shahid","year":"2022","journal-title":"J Taibah Univ Med Sci"},{"key":"2025050208370668200_hvaf024-B46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/10641955.2013.784788","article-title":"Clinical characterization and outcomes of preeclampsia with normal angiogenic profile","volume":"32","author":"Rana","year":"2013","journal-title":"Hypertens Pregnancy"},{"key":"2025050208370668200_hvaf024-B47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10641955.2016.1148162","article-title":"Kryptor-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes","volume":"35","author":"Salahuddin","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"2025050208370668200_hvaf024-B48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/uog.26032","article-title":"Clinical utility of sflt-1 and plgf in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction","volume":"61","author":"Stepan","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation"},{"key":"2025050208370668200_hvaf024-B50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.preghy.2018.05.008","article-title":"Angiogenic biomarkers in triage and risk for preeclampsia with severe features","volume":"13","author":"Rana","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B51","doi-asserted-by":"crossref","first-page":"573 e1","DOI":"10.1016\/j.ajog.2022.10.044","article-title":"The additive role of angiogenic markers for women with confirmed preeclampsia","volume":"228","author":"Suresh","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B52","author":"FDA"},{"key":"2025050208370668200_hvaf024-B53","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/AOG.0000000000005576","article-title":"ACOG clinical practice update: biomarker prediction of preeclampsia with severe features","volume":"143","author":"American College of Obstetricians and Gynecologists","year":"2024","journal-title":"Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B54","author":"National Institute for Health and Care Excellence"},{"key":"2025050208370668200_hvaf024-B55","author":"Health Quality Ontario"},{"key":"2025050208370668200_hvaf024-B56","first-page":"1","article-title":"Placental growth factor (plgf)-based biomarker testing to help diagnose pre-eclampsia in people with suspected pre-eclampsia: a health technology assessment","volume":"23","author":"Ontario Health (Quality)","year":"2023","journal-title":"Ont Health Technol Assess Ser"},{"key":"2025050208370668200_hvaf024-B57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/10641950802366252","article-title":"Utilization of health care services of pregnant women complicated by preeclampsia in Ontario","volume":"28","author":"Liu","year":"2009","journal-title":"Hypertens Pregnancy"},{"key":"2025050208370668200_hvaf024-B58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejogrb.2014.04.033","article-title":"Care-as-usual provided to formerly preeclamptic women in The Netherlands in the next pregnancy: health care consumption, costs and maternal and child outcome","volume":"179","author":"Delahaije","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025050208370668200_hvaf024-B59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B60","doi-asserted-by":"crossref","first-page":"101124","DOI":"10.1016\/j.preghy.2024.101124","article-title":"Signs or symptoms of suspected preeclampsia\u2014a retrospective national database study of prevalence, costs, and outcomes","volume":"36","author":"Khosla","year":"2024","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.preghy.2019.03.002","article-title":"Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: a health economics review","volume":"17","author":"Schlembach","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B62","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/1471-0528.12259","article-title":"Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia","volume":"120","author":"Schnettler","year":"2013","journal-title":"BJOG"},{"key":"2025050208370668200_hvaf024-B63","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12913-018-3406-1","article-title":"Economic assessment of the use of the sflt-1\/plgf ratio test to predict preeclampsia in Germany","volume":"18","author":"Schlembach","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2025050208370668200_hvaf024-B64"},{"key":"2025050208370668200_hvaf024-B65","doi-asserted-by":"crossref","first-page":"e0164276","DOI":"10.1371\/journal.pone.0164276","article-title":"Placental growth factor (plgf) in women with suspected pre-eclampsia prior to 35 weeks\u2019 gestation: a budget impact analysis","volume":"11","author":"Duckworth","year":"2016","journal-title":"PLoS One"},{"key":"2025050208370668200_hvaf024-B66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preghy.2018.04.014","article-title":"Economic evaluation of sflt-1\/plgf ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals","volume":"13","author":"Figueira","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"2025050208370668200_hvaf024-B67","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1080\/14767058.2016.1242122","article-title":"Budget impact analysis of sflt-1\/plgf ratio as prediction test in Italian women with suspected preeclampsia","volume":"30","author":"Frusca","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025050208370668200_hvaf024-B68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/uog.15997","article-title":"Sflt-1\/plgf ratio test for pre-eclampsia: an economic assessment for the UK","volume":"48","author":"Vatish","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B69","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3111\/13696998.2010.535285","article-title":"Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective","volume":"13","author":"Hadker","year":"2010","journal-title":"J Med Econ"},{"key":"2025050208370668200_hvaf024-B70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/10641955.2011.638958","article-title":"Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective","volume":"32","author":"Hadker","year":"2013","journal-title":"Hypertens Pregnancy"},{"key":"2025050208370668200_hvaf024-B71","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/AOG.0000000000005532","article-title":"Angiogenic biomarkers in preeclampsia","volume":"143","author":"Burwick","year":"2024","journal-title":"Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.preghy.2021.10.009","article-title":"Cost effectiveness of the sflt1\/plgf ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States","volume":"26","author":"Khosla","year":"2021","journal-title":"Pregnancy Hypertens"},{"issue":"2S","key":"2025050208370668200_hvaf024-B73","doi-asserted-by":"crossref","first-page":"S1037","DOI":"10.1016\/j.ajog.2020.10.028","article-title":"Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction","volume":"226","author":"Dathan-Stumpf","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B74","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.ajog.2022.01.026","article-title":"A machine-learning-based algorithm improves prediction of preeclampsia-associated adverse outcomes","volume":"227","author":"Schmidt","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2025050208370668200_hvaf024-B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.07.015","article-title":"Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1\/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy","author":"Burns","year":"17, 2024","journal-title":"[Epub] Am J Obstet Gynecol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/5\/548\/62630666\/hvaf024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/5\/548\/62630666\/hvaf024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:33:44Z","timestamp":1746192824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/71\/5\/548\/8092918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,25]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaf024","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,25]]}}}